Breath Collection from Children for Disease Biomarker Discovery
February 14th, 2019
6.7K views
This protocol describes a simple method for the acquisition of breath samples from children. Briefly, samples of mixed air are pre-concentrated in sorbent tubes prior to gas chromatography-mass spectrometry analysis. Breath biomarkers of infectious and non-infectious diseases can be identified using this breath collection method.
Overview
This protocol outlines a noninvasive method for collecting breath samples from children, which can be analyzed for biomarkers of various diseases. The technique is designed to be simple and reproducible, facilitating comparisons across studies.
Key Study Components
Area of Science
- Neuroscience
- Biology
- Pediatrics
Background
- Breath analysis can provide insights into pediatric medical conditions.
- The method is noninvasive, making it suitable for children.
- Standardized techniques enhance the reliability of results.
- Visual instructions aid in the setup of complex equipment.
Purpose of Study
- To develop a method for noninvasive breath sample collection in children.
- To facilitate the diagnosis of various diseases.
- To enable comparisons of results across different studies.
Methods Used
- Collection of mixed air samples using sorbent tubes.
- Gas chromatography-mass spectrometry for analysis.
- Assembly of breath sample equipment with specific components.
- Use of visual aids for equipment setup.
Main Results
- Successful collection of breath samples from children.
- Identification of biomarkers related to infections and metabolic disorders.
- Demonstration of the method's reproducibility and simplicity.
- Potential applications in point-of-care testing.
Conclusions
- The breath collection method is effective for pediatric use.
- It opens avenues for noninvasive diagnostics in various diseases.
- Standardization can improve research comparability.
Frequently Asked Questions
What are the advantages of this breath collection method?
It is noninvasive, simple, and reproducible, making it suitable for children.
What diseases can be diagnosed using this method?
It can identify biomarkers for infections, metabolic disorders, and cancer.
How is the breath sample collected?
Samples are collected using sorbent tubes attached to a breath sampler.
Is visual instruction necessary for this method?
Yes, visual aids help in setting up the complex equipment.
Can this method be used for clinical testing?
Yes, it has potential applications for point-of-care testing.
How does this method compare to traditional sampling techniques?
It is less invasive and allows for easier sample collection from children.
Executive Industry Relevance
Noninvasive breath sampling enables early detection of pediatric disease biomarkers, supporting target validation in infectious, metabolic, and oncologic indications. The method’s reproducibility and minimal patient cooperation requirements enhance feasibility in resource-limited settings, facilitating cross-study comparability and translational continuity. Standardized collection reduces variability in volatile organic compound (VOC) profiling, improving predictive confidence in biomarker discovery pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of disease-associated VOC profiles to support hypothesis generation in pediatric populations.
- Operational Value: Provides a reproducible, noninvasive matrix for biomarker discovery without requiring invasive procedures.
- Predictive Value: Facilitates early-stage target validation by correlating breath VOC patterns with clinical phenotypes.
Screening & Assay Development
- Scientific Value: Generates stabilized breath samples suitable for GC-MS analysis, enabling untargeted VOC screening.
- Operational Value: Supports assay standardization through controlled sample volume, timing, and thermal desorption tube transfer within one hour.
- Scalability: Uses portable equipment, allowing deployment in field settings and multi-site studies.
Translational & Preclinical Research
- Translational Continuity: Bridges discovery and preclinical validation by providing human-relevant breath VOC data from pediatric cohorts.
- Biomarker Alignment: Enables identification of VOCs like isoprene and beta-pinene as potential translational biomarkers with fold-change validation against ambient controls.
- Risk De-risking: Reduces mechanistic ambiguity in biomarker studies through standardized, quantifiable outputs.
Pipeline & Workflow Integration
The method fits within the discovery workflow from hypothesis testing to lead identification, providing quantitative VOC measurements that inform target selection and assay readiness.
- Discovery Biology: Supports hypothesis testing by enabling comparison of breath VOC profiles between disease and control states.
- Screening: Produces standardized breath samples amenable to GC-MS, ensuring reproducible chemical readouts for compound screening.
- Analytics: Delivers quantitative VOC measurements (e.g., isoprene at 10x, beta-pinene at 3x ambient levels) that enable cross-sample comparison and threshold setting.
- Translational Research: Connects to preclinical work by establishing human-relevant VOC signatures that can be validated in model systems.
- Enterprise Reuse: Establishes a reusable sampling protocol applicable across infectious, metabolic, and neoplastic disease programs in pediatrics.
Operational & Enterprise Impact
- Scientific Value: Increases target confidence through reproducible, noninvasive biomarker detection in pediatric populations.
- Operational Value: Ensures standardization via fixed collection volume, timed transfer, and cold storage until GC-MS analysis.
- Strategic Value: Improves go/no-go decisions by reducing biological variability in early biomarker discovery.
- Portfolio Impact: Enables risk-adjusted prioritization of VOC targets based on fold-change and reproducibility across cohorts.
Implementation Considerations
- Requires training in breath sampler assembly, valve operation, and sample labeling to ensure reproducibility.
- Depends on access to thermal desorption tubes, pumps, and GC-MS infrastructure for downstream analysis.
- Necessitates cross-team standardization of collection timing, breath volume, and ambient air controls.
- Adaptation considerations include pediatric cooperation, equipment portability, and environmental VOC interference in field settings.
- Practical limitation: Sample integrity depends on transfer to sorbent tubes within one hour of collection to prevent analyte loss.
Biopharma FAQs
Why is replication of breath collection important for target validation?
Replication ensures consistent VOC profiles across subjects, reducing false discoveries and increasing confidence in biomarker-disease associations. The protocol recommends collecting at least one liter of breath per child and noting breath count to standardize input. This supports reliable comparison between disease and control groups in early discovery.
How does isolation of alveolar breath improve biomarker detection in pediatric samples?
The method uses a two-way valve and bag system to collect end-tidal breath, minimizing contamination from ambient air or dead space. This isolation enhances the specificity of alveolar VOCs like isoprene and beta-pinene, which are elevated in breath versus room air. Such refinement improves signal-to-noise ratio in biomarker discovery.
What quantitative measurements from breath samples enable lead identification?
GC-MS analysis provides quantitative VOC concentrations, such as the 10-fold increase in isoprene and 3-fold increase in beta-pinene in pediatric breath versus ambient controls. These fold-change metrics help prioritize biomarkers with strong disease association for further validation. Quantitative outputs support structure-activity relationship modeling and lead optimization.
Why are ambient air controls required before implementing breath sampling in multi-site studies?
Ambient air samples collected using the same pump and tube setup control for environmental VOC contamination, ensuring that detected compounds originate from breath. In the study, ambient controls confirmed that isoprene and beta-pinene elevations were breath-derived. This standardization is essential for cross-site reproducibility and regulatory-aligned biomarker validation.
What statistical analysis is needed to validate breath VOC biomarkers before preclinical advancement?
Comparative statistical analysis between breath and ambient air samples is required to confirm significant VOC enrichment, as demonstrated by the fold-change increases in isoprene and beta-pinene. Such analysis establishes biomarker specificity and reduces noise in discovery datasets. Thresholds based on reproducibility and effect size support go/no-go decisions in target prioritization.
